Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Botry-Zen is a New Zealand-based biotechnology company specializing in the development and manufacture of biological control agents for the agricultural and horticultural sectors. The company's core technology is based on the saprophytic fungus Ulocladium oudemansii, which acts as a biological antagonist against Botrytis cinerea (Grey Mould) and other fungal pathogens. Their product suite, including Botry-Zen, Mid-Zen, and Armour-Zen, provides environmentally sustainable alternatives to synthetic fungicides for use in viticulture and berry production. Botry-Zen focuses on integrated pest management (IPM) strategies to reduce chemical residues in food crops and improve export quality.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Botry Zen.